undamentalytics Newsletter
Sign in

Clinuvel Pharmaceuticals Ltd balance sheet

At the end of fiscal 2026, Clinuvel Pharmaceuticals Ltd had total assets of $204m, total liabilities of $15.4m and shareholders' equity of $189m. It held $13.9m in cash against $0 of debt: net cash of $13.9m.

Balance sheet

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2024Jun 20242025Jun 20252026Jun 2026
Cash and equivalents—1814
Receivables181816
Inventory—65
Total current assets—171197
Total assets—177204
Deferred revenue (current)—00
Total current liabilities—1813
Total debt—00
Total liabilities—2015
Shareholders' equity135157189
Net debt (negative = net cash)—−18−14
Shares outstanding—50m50m

Balances at each fiscal year end (quarter end in the quarterly view). Total debt is short- plus long-term borrowings, including lease debt where the company reports it within debt. Where assets do not equal liabilities plus shareholders' equity, the difference (non-controlling interests, redeemable preferred shares) is shown on its own line.

Compare with peers

Head to head: ABCL vs CUVLCUVL vs CYTKCUVL vs RXRXCUVL vs NTLA

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Clinuvel Pharmaceuticals Ltd's SEC filings (10-K and 10-Q), retrieved November 1, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Clinuvel Pharmaceuticals Ltd.